PBAC's latest decision on Pramipexole hydrochloride: Recommended with restriction (2009). Considered for monotherapy for idiopathic Parkinson disease in patients with motor disability and no evidence of cognitive impairment.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
4
first 2007
Submissions
4
2007 → 2009
Eligible population
patients with motor disability and no evidence of cognitive impairment due to idiopathic Parkinson disease
Therapy area
Neurology
Line of therapy
Not applicable
Evidence base
RCT, Meta-analysis
Primary endpoint
QoL, Safety
Key trials
CALM-PD, PKDS009
Comparator
cabergoline
Economic model
Cost-minimisation
ICER note
Cost minimisation analysis presented; no ICER calculated by design.
ICER (historical)
$15k/QALY–$45k/QALY in an earlier submission (2007) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Submission history
Jul 2007: Not recommended · Authority required — ICER $45k/QALY
Jul 2008: Not recommended · Restricted
Nov 2008: Recommended with restriction · Restricted
Jul 2009: Recommended with restriction · Restricted